Dexcom 3Q 2026: Revenue $1.34B, Net income $275.1M, EPS $0.72 - 10-Q Summary
Article excerpt
Highlighted: the sentence this signal was extracted from
Dexcom 3Q 2026: Revenue $1.34B, Net income $275.1M, EPS $0.72 - 10-Q Summary Less than 1 min read DXCM Dexcom reported third-quarter 2026 revenue of $1.34 billion, up 11.2% year over year, while net income declined 3.1% to $275.1 million and diluted EPS increased 2.9% to $0.72. Financial Highlights Metric Current quarter Prior year quarter YoY change Revenue¹ $1.34B $1.21B 11.2% Net income² $275.1M $283.8M (3.1%) Diluted EPS³ $0.72 $0.7 2.9% ¹ Reported as "Revenue". ² Reported as "Net income". ³ Reported as "Diluted net income per share". Business Highlights Distributor revenue increased to $1.15 billion from $1.03 billion, while direct revenue rose to $196.5 million from $183.3 million. G7 15 Day contributed to stronger gross margin, alongside higher volumes, improved manufacturing efficiency and favorable product mix. Stelo, Dexcom's over-the-counter biosensor, received FDA clearance in June 2026 for children aged 2 and older who do not use insulin. Dexcom plans to scale manufacturing for rising demand and continue investing in product development, connected platforms and predictive CGM insights. Original SEC Filing: DEXCOM INC [ DXCM ] - 10-Q - Oct. 29, 2026 Disclaimer This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. Earnings...
Keep reading with a free account
The rest of this article, and every signal for Dexcom, is in your free account.
